Successful management of imatinib despite alopecia and nail necrosis
Transfusion and Apheresis Science, cilt.48, sa.2, ss.271-272, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 48 Sayı: 2
- Basım Tarihi: 2013
- Doi Numarası: 10.1016/j.transci.2013.01.002
- Dergi Adı: Transfusion and Apheresis Science
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.271-272
- Anahtar Kelimeler: Alopecia, CML, Imatinib mesylate, Paronychia inflammation, Side effects
- Süleyman Demirel Üniversitesi Adresli: Hayır
Özet
Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd.